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Abstract 
Aim: To investigate the relationship between the presenting clinical and demographic 
characteristics in first episode psychosis patients with their clinical diagnostic grouping 1 year 
later.  
Methods: Data from 1014 patients from seven London-based Early Intervention Services 
were extracted from the MiData audit database. Associations between clinical and 
demographic measures at presentation and clinical diagnosis made at 1 year were assessed 
with ANOVA and Chi-square tests. 
Results: The sample comprised 76% of patients with schizophrenia-spectrum diagnoses, 9% 
with manic psychoses, and 6% with depressive psychoses. Compared to the other two groups, 
patients who were diagnosed as having manic psychosis were younger, with higher education 
and shorter duration of untreated psychosis, and had higher Young Mania Rating Scale scores 
at presentation and lower PANSS-N scores. Patients diagnosed at 1 year as having 
depressive psychosis were older and more likely to be white, with the lowest PANSS-positive 
scores at baseline. Patients diagnosed at 1 year as having schizophrenia spectrum diagnoses 
were more likely to be black males. Patients in the 3 diagnostic subgroups of psychosis 
differed on both clinical and demographic characteristics at presentation.  
Conclusions: There were significant clinical and demographic differences at presentation 
between first episode psychosis patients who received different clinical diagnoses at 1 year. 
Future work will determine the extent to which these differences can be used to guide clinical 
care. 
 
 
Key words: Schizophrenia, Manic Psychosis, Bipolar Affective Disorder, Depressive 
Psychosis, Major Depressive Disorder, First Episode Psychosis, Diagnosis 
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Introduction 
Clinical diagnosis is integral to optimal patient care,1 but in psychiatry the establishment of a 
clear diagnosis may be difficult.2 One reason for this is the fact that many conditions can 
present with similar and overlapping symptoms.3 Psychotic symptoms, notably hallucinations 
and delusions, are experienced in both affective and non-affective conditions, but 
differentiating between these subtypes in first-episode psychosis (FEP) patients is often 
problematic at presentation.4 Although schizophrenia spectrum (SZ) and affective psychoses 
have different genetic risk factors, as well as distinct symptomatic profiles,5 there remains no 
standard clinical test to differentiate these conditions.6 
 
Psychosocial risk factors have long been suggested to play an important role in the 
development of psychotic illness,7-10 and it is possible that different risk factors might 
underlie affective and SZ psychoses, and that these could be used to improve diagnostic 
accuracy at first presentation in psychosis patients. This has the potential to significantly 
improve long-term management.11 Most research to date on the association of psychosocial 
risk factors with psychosis has focused on SZ psychoses.12-15 There have, in addition, been 
several studies comparing psychosocial factors in SZ, manic (MP) and schizoaffective (SA) 
psychoses in FEP.16-24 
 
There are a relatively small number of studies examining psychosocial factors in FEP 
patients with depressive psychosis (DP).25-28 Interestingly, two of these studies found that 
there were more overlapping features between patients with depressive psychosis (DP) and 
SZ than with bipolar disorder.27, 28 This contradicted the general assumption that patients 
with DP are often in the early stages of bipolar disorder.29 These findings may enable 
clinicians to recognise and differentiate between MP, SZ and DP at an earlier stage, 
ultimately influencing future management and recovery. In this study, we aimed to test the 
hypothesis that different clinical diagnoses at 1 year in FEP patients taken on by Early 
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Intervention in psychosis Services (EIS) in London were associated with distinct 
sociodemographic and clinical features at first presentation. 
 
Methods 
Data were drawn from MiData, a computerized audit tool based within Microsoft Access 
which was developed by the London Early Intervention Research Network.30 Baseline 
measures were completed by clinicians based on their routine comprehensive assessments 
within 1 month of entry to EIS (baseline) and then 1 year later (follow-up). All clinicians were 
trained and were expected to reach at least 85% concordance with expert raters and other 
team members before being allowed to complete the measures on their patients.30 
 
The MiData database comprises a naturalistic cohort of referrals to seven inner-city EIS from 
the following NHS (National Health Service) Mental Health Trusts in England: Camden and 
Islington (C&I EIS); South London and Maudsley (Lewisham EIS and STEP); South West 
London and St. George’s (Wandsworth); East London and the City (EQUIP); and Central 
and North West London (Brent and Kensington, Chelsea & Westminster EIS). Service 
eligibility criteria were: (i) aged between 18 and 35 years old; (ii) presenting to the EIS for the 
first time with a psychotic episode lasting at least 7 days; and (iii) resident within the EIS 
catchment area. Patients with psychotic symptoms as a direct result of acute drug 
intoxication were excluded. There were 1108 patients in total in the MiData database. 
 
Basic demographic data were obtained at baseline, including gender, age at entry to EIS, 
educational level, employment status, whether born in the UK, and ethnicity based on the 
2001 UK national census categories. Participants were assessed for the presence or 
absence of: (i) family history of psychosis or any other mental illness in a first-degree 
relative; (ii) any incidents of violence towards others in their lifetime. 
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The degree of hostility in the preceding 2 weeks before presentation was assessed using the 
Brief Psychiatric Rating Scale.31 This variable was quantitatively rated from 1 (none) to 7 
(extremely severe). Substance use was measured with the combined alcohol use and drug 
use scale.32 The lifetime use of Alcohol, Nicotine and Cannabis ('yes'/'no' for each) was 
recorded at presentation. 
 
Duration of Untreated Psychosis (DUP) was assessed with a revised version of the 
Nottingham Onset Schedule.33 DUP was defined as: the number of days between the 
appearance of the first positive psychotic symptom (hallucination, delusion or thought 
disorder) and the date that antipsychotic medication was initiated and thereafter reported to 
have been taken for at least 75% of the subsequent month. 
 
The Positive and Negative Syndrome Scale (PANSS)34 was completed by clinicians at 
baseline to assess positive (PANSS-P) and negative (PANSS-N) psychotic symptoms. The 
Young Mania Rating Scale (YMRS)35 was completed to assess manic symptoms. The 
Global Assessment of Functioning Scale disability subscale (GAF-d)36 was also completed 
at baseline.  
 
ICD-10 (International Classification of Diseases-10)37 diagnosis was recorded at 1-year 
follow up and was extracted from clinical records and confirmed with EIS consultant 
psychiatrists. These were grouped into schizophrenia-spectrum disorders (SZ) (ICD-10 
codes F20-29), manic psychoses (MP) (F30.2, F31.2 or F31.5), depressive psychoses (DP) 
(F32.3, F33.3 or F39), and other disorders (OD) (all other codes).  
 
Ethical Approval 
Data were collected by each EIS in accordance with local audit procedures, which did not 
require patients to consent to collection of the data. Multi-centre ethical permission for 
secondary research use of anonymized versions of these datasets was provided by the 
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Wandsworth Research Ethics Committee. HLF merged together the anonymized data 
supplied by each EIS following written consent from the team managers. 
 
Missing Data 
The supplementary tables reveal the distribution of missing data for each variable between 
the diagnostic categories. Any variable with greater than 50% missing data was not included 
in the subsequent analyses. Chi-square tests were performed to reveal any variables with 
statistically significant differences in missing data between the diagnostic subgroups; any 
such variables were also excluded from the subsequent analyses. 
 
Data Analysis 
The clinical diagnosis at follow-up remained the independent variable throughout. The 
subgroups were initially compared using standard baseline demographic variables: age, 
gender and ethnicity. Additional baseline variables were selected for further subgroup 
comparison. These variables were selected as they either a) presented significant results 
based on a preliminary comparison of all 148 baseline variables or b) were comparable 
factors used in prior studies comparing FEP patients with SZ, DP and MP. A final evaluation 
by Team was conducted to check for bias in the audit data collection. 
 
Analysis for this paper was conducted using SPSS version 22 for Windows. Results are 
expressed as: mean (standard deviation) for continuous variables and as frequency n (%) for 
categorical variables. The p value was calculated for each dependent variable using 
standard procedures; statistical significance was set at p < 0.05. Histogram, box plots and 
QQ plots were used to assess for normality and outliers. For continuous variables, a one-
way analysis of variance (ANOVA) test was used. The effect size was measured with the 
omega-squared measure (ѡ²), rather than eta-squared, to reduce bias. For categorical 
variables, the Pearson chi-square test for association (χ2) was used. The effect size for 
categorical variables (odds ratio) was not calculated as the contingency tables were always 
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greater than 2 x 2. Post-hoc analysis using Tukey’s honestly significant difference (HSD) test 
was performed on variables with statistically significant ANOVA values and a Bonferroni 
correction was used to account for multiple testing. Missing cases were automatically 
excluded by SPSS for each analysis. 
 
Results 
In total, 1014 patients in the MiData database had a diagnosis recorded at 1 year (92% of 
patients in database). Of these, 76% were categorised as SZ (N = 770), 9% as MP (N = 93), 
6% as DP (N = 60) and 9% as OD (N = 91). As the heterogeneous nature of the OD 
subgroup would prevent any robust interpretation of the results, these patients were 
excluded to allow for a clearer comparison of the remaining three subgroups (N = 923). The 
majority of the remaining cohort was male (n = 598, 65%), and the mean age at presentation 
was 23 years old (SD = 4.7). The only significant difference between different EIS was that 
the Camden and Islington service had a lower proportion of SZ patients than the 
Wandsworth (ETHOS) and Hackney (EQUIP) services (Table 1). 
 
There were significant differences between the diagnostic subgroups for age, gender and 
ethnicity at presentation (Table 2). Patients with a diagnosis at 1 year of MP were the 
youngest at presentation (mean [SD] = 22.4 [4.6]), with a greater proportion of female 
patients (46% male). SZ patients were predominantly male (68%) and DP patients were the 
oldest.  
 
There were significant distinctions at presentation for a number of other variables. Level of 
hostility was higher in SZ than DP (p<0.05), although there was also a non-significant trend 
for hostility in MP to be higher than in DP (p<0.1). DUP was lower in MP than SZ or DP 
(p<0.05). Level of education was higher in MP than DP (p<0.05). SZ patients presented with 
a significantly higher incidence of violence in lifetime than DP patients (p<0.05). 
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The three diagnostic subgroups did not differ on country of birth, family history of psychosis 
or any mental illness, employment status, alcohol use, cannabis use and nicotine use (Table 
2). 
 
Table 3 shows a breakdown of the clinical measures at baseline. There was a significant 
difference in baseline PANSS-P scores (F(2, 535) = 5.27, p = 0.005, ѡ = 0.13), PANSS 
negative scores (F(2, 514) = 6.73, p = 0.001, ѡ = 0.15) and YMRS scores (F(2, 532) = 
24.24, p < 0.001, ѡ = 0.28) between diagnostic groups at 1 year. There were no significant 
baseline differences between the subgroups in GAF-d score. 
 
Post-hoc analysis revealed that MP patients had a lower PANSS-N score (mean (SD) = 12.7 
(5.55)) than SZ (mean (SD) = 17.0 (8.21), p = 0.001) and DP patients (mean (SD) = 17.3 
(8.15), p = 0.019). They also had a greater YMRS score than DP and SZ patients (mean 
(SD) = 17.8 (14.04), both p’s < 0.001), and a greater PANSS-P score (mean (SD) = 20.9 
(8.86)) than DP patients (mean (SD) = 15.7 (5.31), p = 0.004). 
  
Discussion  
This is the largest study to date investigating the sociodemographic and clinical features of 
MP, DP and SZ patients at first presentation to EIS in London. A key proportion of patients 
were differentiated from SZ patients as MP (9%), DP (6%) and OD (9%) at 1 year. The 
proportion of patients with each diagnosis did not differ significantly between any of the EIS 
apart from Camden and Islington, most likely due to a difference in referral pattern or 
acceptance thresholds. 
 
We found that MP patients differed most markedly from the SZ and DP subgroups, having 
shorter DUP, higher ratings on the YMRS, and lower negative symptoms (as measured by 
PANSS-N). The use of DUP as a measure of time should be interpreted with caution as it 
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excludes any change in mood symptoms, which may present months before an acute manic 
episode.38 Our finding that DP and SZ patients were more similar to each other than to MP 
patients is in keeping with earlier reports comparing psychosocial risk factors and 
psychopathology in FEP patients.27, 28 It is important, however, to appreciate the potential 
limitations of using the PANSS to assess negative symptoms in patients with depression. 
Confounding features shared between depression and negative symptoms diminish its 
specificity, especially as other key domains of negative symptomatology are absent.39 Thus 
the relatively higher PANSS-N scores in the DP group in this study may have been due, at 
least in part, to depressive rather than negative symptoms.  
 
 
In this study, the baseline demographics of each diagnostic subgroup were generally in 
keeping with previous reports: the majority of patients with SZ were black males of African 
origin;3, 16, 18, 19, 23-26, 28 MP patients were youngest at presentation but  had achieved the 
highest level of education;16, 18, 23, 26 MP patients had shorter DUP, and subsequently better 
outcomes.25, 40, 41 
 
The number of baseline variables producing a statistically significant difference involving all 
three diagnostic subgroups was limited. Furthermore, the calculated effect size of these 
differentiating variables was often small. These results underscore the multifaceted aetiology 
of these conditions and demonstrate the degree of overlap between the subgroups. In this 
study, SZ patients often occupied an intermediate level between DP and MP patients, and 
previous research has already proposed schizoaffective disorder as the intermediate 
between SZ and MP.19, 22-24 These findings contribute to the ongoing discussion concerning 
the existence of a psychosis spectrum.9, 14 
 
The idea of the psychosis continuum has been developed as an alternative approach to 
categorical diagnosis in psychotic illness. It argues that the psychopathological profile at 
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presentation is a better predictor of outcome than diagnostic subgroup,42-44 and highlights a 
subset of the population with psychotic symptoms below the DSM criteria.9 The diagnostic 
stability of the subgroups has also previously been questioned,3 although a recent study 
reaffirmed the high diagnostic stability of SZ and affective psychoses.45 Furthermore, 
patients with first-episode psychosis generally prefer to be told their diagnosis.46 
Nonetheless, it is worth remembering that future work will possibly redefine diagnostic 
categories in psychiatry based on underlying biological processes rather than superficial 
psychopathology.47 
 
Although this study illustrates the potential overlap in psychosocial variables, there were 
significant differences at presentation between the subgroups, supporting a more categorical 
distinction.48 Ultimately, the critical objective is optimal treatment management. Studies have 
already illustrated the variable response to Lithium by SZ patients compared to bipolar 
patients.49 Further evaluation of the diagnostic stability, reliability and prognostic value of the 
diagnostic subgroups is required to determine the best outcome of this debate. 
 
Although this naturalistic study design contained a large cohort, and was therefore 
reasonably representative of the study population, there were a number of limitations which 
deserve attention. The first set of limitations relate to the collection of the primary data used. 
The audit data was compiled by clinicians, not researchers. The current study centres 
around the clinical diagnosis at follow-up, however the factors employed to determine this 
outcome are largely unknown. For example, it would have also been interesting to note any 
changes to the preliminary working diagnosis. Additionally, the relatively small sample size 
of MP and DP patients warrants replication of these results using larger cohorts of patients 
with these diagnoses. Finally, the dataset contained a large amount of missing data; it is 
possible that a number of variables were not representative of the population. However, this 
bias was minimised as (i) the key demographics of the missing data did not vary from those 
of the whole cohort, (ii) no more than 50% of data was missing for any variable and (iii) there 
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were no significant differences in missing data between the diagnostic subgroups. Missing 
data is common for audit data, especially in those of longitudinal design.  
 
Conclusion 
Patients presenting to EIS in London show distinct differences in both demographic variables 
and psychopathology at presentation between those who are eventually diagnosed with DP, 
MP and SZ. These findings may provide clinicians with supplementary tools to more 
accurately classify psychosis at initial presentation and design appropriate packages of care. 
In particular, early and accurate diagnosis of DP patients is critical; this condition is often 
underreported and undertreated.50 Further work to elucidate distinctions in the pathogenesis 
and aetiology of each disorder is vital to our understanding of these complex conditions. 
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Table 1: The diagnostic outcomes allocated from each of the seven London-based EIS 
teams 
  Clinical diagnosis  
 n SZ 
N=770 
MP 
N=93 
DP 
N=60 
 χ2 (df)  
EIS, n (%) χ2 = 27.60 (12)* 
C&I  232 177 (76.3) 29 (12.5) 26 (11.2)  
EQUIP  140 125 (89.3) 10 (7.1) 5 (3.6) 
ETHOS 107 98 (91.6) 5 (4.7) 4 (3.7) 
KCW 101 78 (77.2) 14 (13.9) 9 (8.9) 
Lewisham 239 202 (84.5) 27 (11.3) 10 (4.2) 
STEP 79 70 (88.6) 6 (7.6) 3 (3.8) 
Brent  25 20 (80.0) 2 (8.0) 3 (12.0) 
Significant 
differences 
between 
groups 
 ETHOS, 
EQUIP > C&I 
   
n, frequency; P, P-value (* < 0.05, ** < 0.005, *** < 0.001); SZ, schizophrenia-spectrum; MP, manic 
psychosis; DP, depressive psychosis; EIS, Early Intervention Service; C&I, Camden & Islington EIS; 
EQUIP, Hackney EIS; ETHOS, Wandsworth EIS; KCW, Kensington, Chelsea & Westminster EIS; 
STEP, Southwark EIS; Brent, London borough of Brent EIS. 
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Table 2: Sociodemographic characteristics at baseline for cases based on follow-up 
diagnosis 
 n Clinical diagnosis 
N = 923 
  
 
SZ 
N=770 
MP 
N=93 
DP 
N=60 
F/χ2 (df) Significant 
differences 
between 
groups 
Age, years, 
mean (SD) 
922 23.3 (4.7) 22.4 (4.6) 24.7 (5.4) 4.47 (2)* DP > MP 
Gender, n (%)     χ2 = 25.34 
(2)*** 
 
Male  598 526 (68.3) 43 (46.2) 29 (48.3)  SZ > MP, 
DP 
Female  325 224 (31.7) 50 (53.8) 31 (51.7)  MP, DP > 
SZ 
Ethnicity, n 
(%) 
    χ2 = 25.68 
(14)* 
 
White British  187 157 (20.4) 14 (15.1) 16 (26.7)   
White Other  104 76 (9.9) 13 (14.0) 15 (25.0)  DP > SZ 
Mixed 82 68 (8.9) 11 (11.8) 3 (5.0)   
Asian 103 90 (11.7) 9 (9.7) 4 (6.7)   
Black 
Caribbean  
94 80 (10.4) 10 (10.8) 4 (6.7)   
Black African 246 213 (27.7) 20 (21.5)  13 (21.7)   
Black Other  74 60 (7.8) 12 (12.9) 2 (3.3)   
Other  31 24 (3.1) 4 (4.3) 3 (5.0)   
DUP, days, 
mean (SD) 
615 104.8 
(113.1) 
31.3 (38.1) 116.1 
(120.0) 
13.72 (2)*** MP < SZ, 
DP 
Hostility, 
mean (SD)¹ 
648 2.3 (1.8) 2.3 (1.9) 1.6 (0.9) 4.14 (2)* SZ > DP 
Education², 
mean (SD) 
794 2.9 (1.8) 3.2 (1.9) 2.5 (1.5) 2.82 (2) MP > DP 
Born in UK, n 
(%) 
    χ2 = 4.03 (2)  
Yes 527 446 (60.8) 53 (60.2) 28 (47.5)   
No 354 288 (39.2) 35 (39.8) 31 (52.5)   
FH of 
Psychosis, n 
(%) 
    χ2 = 0.54 (2)  
Yes 176 148 (22.0) 18 (24.3) 10 (18.9)   
No 623 524 (78) 56 (75.7) 43 (81.1)   
FH of any mental illness, n (%)   χ2 = 1.71 (2)  
Yes 170 140 (20.9) 20 (27.0) 10 (18.9)   
No 628 531 (79.1) 54 (73.0) 43 (81.1)   
Employment status, n (%)   χ2 = 3.15 (4)  
Employed 121 100 (14.2) 11 (13.8) 10 (17.5)   
Unemployed 537 456 (64.9) 46 (57.5) 35 (61.4)   
Other 182 147 (20.9) 23 (28.7) 12 (21.1)   
Violence in lifetime, n (%)   χ2 = 6.63 (2)*  
Yes  249 219 (40.9) 21 (38.9) 9 (20.9)  SZ > DP 
No  384 317 (59.1) 33 (61.1) 34 (79.1)  DP > SZ 
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Alcohol use, n (%)   χ2 = 3.71 (2)  
Yes  333 275 (57.5) 36 (67.9) 22 (48.9)   
No  243 203 (42.5) 17 (32.1) 23 (51.1)   
Nicotine use, n (%)   χ2 = 1.42 (2)  
Yes  210 179 (37.5) 18 (34.6) 13 (28.9)   
No  364 298 (62.5) 34 (65.4) 32 (71.1)   
Cannabis use, n (%)   χ2 = 3.35 (2)  
Yes 330 279 (58.5) 31 (58.5) 20 (44.4)   
No 245 198 (41.5) 22 (41.5) 25 (55.6)   
n, frequency; SZ, schizophrenia-spectrum; MP, manic psychosis; DP, depressive psychosis; GAF-d, 
Global Assessment of Functioning Scale–disability subscale; PANSS, Positive and Negative 
Syndrome Scale; YMRS, Young Mania Rating Scale; DUP, Duration of Untreated Psychosis (time 
between first psychotic symptom and compliance with medication); P, p-value (* < 0.05, ** < 0.005, *** 
< 0.001); df, degrees of freedom; SD, standard deviation; ¹, degree of symptom in preceding 2 weeks 
(0-7); ², highest level of qualification scale (1-7): no qualifications (1), GCSES (2), A-levels (3), 
professional qualification/Higher National Diploma (4), degree incomplete (5), degree complete (6), 
post-grad training (7); FH, family history. 
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Table 3: Clinical measures breakdown at baseline and follow-up based on clinical 
diagnosis at 1 year. 
  Clinical diagnosis 
N = 923 
 
 
 n SZ 
N=770 
MP 
N=93 
DP 
N=60 
F (df = 2) Significant 
differences 
between 
groups 
PANSS-P, mean (SD)   
Baseline 538 18.4 (7.7) 20.9 (8.9) 15.7 (5.3) 5.27** DP < MP 
PANSS-N, mean (SD)   
Baseline 517 17.0 (8.2) 12.7 (5.6) 17.3 (8.1) 6.73*** MP < SZ, 
DP 
YMRS, mean (SD)   
Baseline 535 9.2 (8.5) 17.8 (14.0) 6.0 (5.3) 24.24*** MP > SZ, 
DP 
GAF-d, mean (SD)   
Baseline 537 49.9 (17.7) 52.2 (18.9) 47.1 (16.2) 0.96  
n, frequency; SZ, schizophrenia-spectrum; MP, manic psychosis; DP, depressive psychosis; PANSS, 
Positive and Negative Syndrome Scale; YMRS, Young Mania Rating Scale; GAF-d, Global 
Assessment of Functioning Scale disability subscale; P, p-value (* < 0.05, ** < 0.005, *** < 0.001); 
SD, standard deviation; df, degrees of freedom. 
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